Previous close | 0.3399 |
Open | 0.3440 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.3020 - 0.3440 |
52-week range | 0.2210 - 2.7900 |
Volume | |
Avg. volume | 188,823 |
Market cap | 3.605M |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.5800 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.00 |
ANN ARBOR, Mich., May 02, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of five new patents, including three in Europe and two in China. ENDRA’s intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the TAEUS system with its novel thermoacoustic technology.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript March 28, 2024 ENDRA Life Sciences Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.36. NDRA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome […]
Q4 2023 ENDRA Life Sciences Inc Earnings Call